CA2324995A1 - Methodes et produits concernant les interactions metaboliques dans les maladies - Google Patents

Methodes et produits concernant les interactions metaboliques dans les maladies Download PDF

Info

Publication number
CA2324995A1
CA2324995A1 CA002324995A CA2324995A CA2324995A1 CA 2324995 A1 CA2324995 A1 CA 2324995A1 CA 002324995 A CA002324995 A CA 002324995A CA 2324995 A CA2324995 A CA 2324995A CA 2324995 A1 CA2324995 A1 CA 2324995A1
Authority
CA
Canada
Prior art keywords
cell
hla
mhc class
cells
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002324995A
Other languages
English (en)
Inventor
Martha K. Newell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont and State Agricultural College
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2324995A1 publication Critical patent/CA2324995A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Abstract

La présente invention concerne des méthodes de régulation de la croissance et de la division cellulaires qui permettent de maîtriser des processus morbides par manipulation du métabolisme mitochondrial et par expression des protéines immunitaires de la surface cellulaire. L'invention concerne également des compositions et des essais de criblage connexes.
CA002324995A 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies Abandoned CA2324995A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8225098P 1998-04-17 1998-04-17
US9451998P 1998-07-29 1998-07-29
US10158098P 1998-09-24 1998-09-24
US60/094,519 1998-09-24
US60/082,250 1998-09-24
US60/101,580 1998-09-24
PCT/US1999/006874 WO1999053953A2 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies

Publications (1)

Publication Number Publication Date
CA2324995A1 true CA2324995A1 (fr) 1999-10-28

Family

ID=27374244

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002324995A Abandoned CA2324995A1 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies

Country Status (5)

Country Link
EP (1) EP1077724A2 (fr)
JP (1) JP2002512203A (fr)
AU (1) AU768656B2 (fr)
CA (1) CA2324995A1 (fr)
WO (1) WO1999053953A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
US6599710B1 (en) * 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
CA2375508A1 (fr) 1999-06-23 2000-12-28 Martha K. Newell Procedes et produits permettant la manipulation de l'expression de proteines ucp
US6365796B1 (en) 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US6670138B2 (en) 2000-11-01 2003-12-30 Agy Therapeutics, Inc. Method of diagnosing ischemic stroke via UCP-2 detection
CA2457799C (fr) 2001-08-21 2014-05-27 Ventana Medical Systems, Inc. Methode et essai de quantification permettant d'evaluer l'etat du systeme c-kit/scf/pakt
WO2005077065A2 (fr) * 2004-02-09 2005-08-25 The Regents Of The University Of California Ligands polyvalents selectifs a haute affinite et methodes de fabrication
BRPI0712629C1 (pt) * 2006-06-20 2021-07-27 Genentech Inc método para a detecção da apoptose e método para a identificação de uma célula de câncer humano
ES2554168T3 (es) * 2008-04-18 2015-12-16 Baxter International Inc. Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
ES2613844T3 (es) 2008-04-21 2017-05-26 Lawrence Livermore National Security, Llc Ligandos polidentados de alta afinidad selectivos y métodos para producirlos
MY181093A (en) * 2011-03-02 2020-12-17 Berg Llc Interrogatory cell-based assays and uses thereof
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US20170160174A1 (en) * 2014-06-27 2017-06-08 National University Corporation Nagoya University Embedding medium for specimen preparation, method for preparing curable base material nonpenetrating specimen, method for preparing curable base material penetrating specimen, curable base material nonpenetrating specimen, thin slice performance improver for frozen embedding medium, and frozen embedding medium
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
KR102410778B1 (ko) 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002579A1 (fr) * 1996-07-12 1998-01-22 Emory University Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere

Also Published As

Publication number Publication date
AU768656B2 (en) 2003-12-18
EP1077724A2 (fr) 2001-02-28
AU3370599A (en) 1999-11-08
WO1999053953A2 (fr) 1999-10-28
JP2002512203A (ja) 2002-04-23
WO1999053953A3 (fr) 2000-01-13

Similar Documents

Publication Publication Date Title
US20120329733A1 (en) Methods and products related to metabolic interactions in disease
Medana et al. MHC class I‐restricted killing of neurons by virus‐specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway
AU768656B2 (en) Methods and products related to metabolic interactions in disease
Jonsson et al. Natural killer cell tolerance: licensing and other mechanisms
Bour‐Jordan et al. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells
Anumanthan et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes
US7722868B2 (en) Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof
LaSalle et al. Early signaling defects in human T cells anergized by T cell presentation of autoantigen.
Sansom et al. The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
Minas et al. Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?
EP1685159B1 (fr) Polypeptides de Tim-3
CA2558371C (fr) Procedes de modulation de reponses immunitaires par la modulation de la fonction tim-1 et tim-4
JP2003510047A (ja) Ｇｌ５０分子およびその使用
AU2004201144B2 (en) Methods and products related to metabolic interactions in disease
Arsov et al. Altered effector responses of HY transgenic CD8+ cells.
Chambers et al. The lymphoproliferative defect in CTLA-4–deficient mice is ameliorated by an inhibitory NK cell receptor
Nieland et al. AT cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70
Kumaresan et al. Molecular characterization of the rat NK cell receptor 2B4
Engelhardt Characterizing the Function and Trafficking of CTLA-4 in T Cells
Cheung Molecular mechanisms of endothelial cytoprotection by CD31-mediated signals
Messina et al. Mechanisms of developmental cell death
Boshell Activation and apoptosis requirements in human T lymphocytes
Sullivan Characterizing the Function of CTLA-4 in Vitro and in Vivo
sephCCabe 2/z, IZ-crtn
Egen CTLA-4 localization and trafficking in T cells

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead